与阿杜卡努马布免疫疗法相关的粉样蛋白相关的成像异常的成像谱
Houman Sotoudeh1, Mohammadreza Alizadeh2, Ramin Shahidi3
1Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, United States.
Frontiers in radiology
|January 22, 2024
概括
阿尔茨海默氏病 (AD) 用阿杜卡努马布治疗有希望,但可能导致粉样蛋白相关成像异常 (ARIA). 神经放射学家必须识别ARIA的成像功能,以有效管理患者.
科学领域:
- 神经学 神经学
- 放射学 放射学是一门学科.
- 免疫治疗是一种免疫疗法.
背景情况:
- 阿尔茨海默病 (AD) 管理正在转向疾病修饰疗法.
- 针对粉样β (Aβ) 的单克隆抗体是研究的一个关键领域.
- 美国食品和药物管理局批准的免疫疗法阿杜卡努马布 (Aducanumab) 显示出有效性,但存在风险.
研究的目的:
- 在接受aducanumab的患者中审查粉样蛋白相关成像异常 (ARIA) 的放射性表现.
- 为了提高神经放射学家对ARIA诊断的熟悉度.
- 支持在阿尔茨海默氏症治疗中安全有效地使用阿杜卡努马布.
主要方法:
- 放射学发现的图像综述.
- 在接受aducanumab治疗的患者中分析ARIA.
- 专注于神经放射学诊断标准.
主要成果:
- 阿杜卡努马布治疗与ARIA有关.
- 在放射学评估中,ARIA提出了特定的特征性成像发现.
- 熟悉这些发现对于诊断至关重要.
结论:
- 神经放射学家对于识别与阿杜卡努马布治疗相关的ARIA至关重要.
- 了解ARIA的成像表现对于患者安全和治疗监测至关重要.
- 本综述为ARIA的放射性特征提供了一份指南.
相关概念视频
01:26Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195